- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04381052
Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
A Randomized Placebo-Controlled Safety and Dose-Finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
Study Overview
Detailed Description
The limited understanding of the clinical behavior of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (the viral organism responsible for COVID-19 disease) is evolving on a daily basis. Reports from China indicate that a subset of patients with the worst clinical outcomes may manifest cytokine storm syndrome. Hypotheses that excess cytokines may trigger a secondary hemophagocytic lymphohistiocytosis (sHLH) have been proposed. Indeed, cytokine profiles consistent with this picture were observed in Chinese patients with severe pulmonary involvement. Specifically, elevated ferritin and interleukin-6 (IL-6) were associated with fatalities among the infected patients. A role for targeted anti-inflammatory and anti-cytokine therapies in the treatment of pulmonary hyperinflammation has been proposed.
Clazakizumab is a genetically engineered humanized immunoglobulin-1 (IgG1) monoclonal antibody (mAb) that binds with high affinity to human IL-6. This investigational agent is currently being studied as a treatment for chronic active antibody mediated rejection of renal allografts.
In this study investigators propose to administer clazakizumab to patients with life-threatening pulmonary failure secondary to COVID-19 disease.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center / New York Presbyerian Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
In order to be eligible to participate in this study, the patients must meet all of the following criteria:
- At least 18 years of age
- Confirmed COVID-19 disease (by Cobas SARS-CoV-2 real time reverse transcription polymerase chain reaction (RT-PCR) using nasopharyngeal swab sample, or equivalent test available to be performed by the Columbia University Irving Medical Center (CUIMC)/New York Presbyterian (NYP) clinical laboratory). Effort will be made to have the confirmatory test result <72 hours prior to enrollment however given overall clinical demand this may not be feasible in all cases.
Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a P/F ratio of <200), OR oxygen saturation (SpO2) < 90% on 4 liters (L) (actual or expected given higher O2 requirement) OR increasing O2 requirements over 24 hours, plus 2 or more of the following predictors for severe disease:
CRP > 35 mg/L Ferritin > 500 ng/mL D-dimer > 1 mcg/L Neutrophil-Lymphocyte Ratio > 4 Lactate dehydrogenase (LDH) > 200 U/L Increase in troponin in patient w/out known cardiac disease
- Has a consent designee willing to provide informed consent on behalf of the patient (this assumes that a mechanically ventilated patients lacks capacity to consent on his/her own behalf. Should it be deemed that the patient has capacity to consent, consent may be obtained from the patient.)
Women of childbearing potential must be willing and able to use at least one highly effective contraceptive method for a period of 5 months following the study drug administration. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly such as:
- combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal)
- progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
- intrauterine device (IUD)
- intrauterine hormone-releasing system (IUS)
- vasectomized partner
- bilateral tubal occlusion
- true abstinence. when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence, such as calendar, ovulation, symptothermal, postovulation methods, and withdrawal are not acceptable methods of contraception.
- Men must be willing to use a double-barrier contraception from enrollment until at 5 months after the last dose of study drug, if not abstinent.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Evidence of irreversible injury deemed non-survivable even if the pulmonary failure recovers (for example severe anoxic brain injury)
- Known active inflammatory bowel disease
- Known active, untreated diverticulitis
- Known untreated bacteremia
- Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis).
- Known hypersensitivity to the clazakizumab
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Clazakizumab 25 mg
The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm.
The route of administration will be intravenous.
Each dose will be administered as an infusion that is run over 30 minutes.
Serum C-reactive protein (CRP) will be evaluated at baseline and on days 1 and 2 following clazakizumab administration.
If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
|
Dose is 25mg intravenously over 30 minutes.
Other Names:
|
Placebo Comparator: Placebo
The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm.
The route of administration will be intravenous.
Each dose will be administered as an infusion that is run over 30 minutes.
Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration.
If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
|
Intravenously administered over 30 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cumulative Incidence of Serious Adverse Events Associated With Clazakizumab or Placebo
Time Frame: 60 days
|
60 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative Incidence of Intubation
Time Frame: 14 days
|
14 days
|
|
Time to Extubation
Time Frame: 14 days
|
14 days
|
|
Length of Intensive Care Unit (ICU) Stay
Time Frame: 14 days
|
14 days
|
|
Number of Patients Who Present a Decrease in C-reactive Protein (CRP)
Time Frame: 14 days
|
14 days
|
|
Number of Patients With Acute Kidney Injury (AKI)
Time Frame: 14 days
|
14 days
|
|
Number of Patients With a Need for Renal Replacement Therapy (RRT)
Time Frame: 14 days
|
14 days
|
|
Duration of Renal Replacement Therapy (RRT)
Time Frame: 60 days
|
60 days
|
|
Patient Survival
Time Frame: 28 days
|
Number of participants alive at day 28.
|
28 days
|
Patient Survival
Time Frame: 60 days
|
Number of participants alive at day 60, end of study.
|
60 days
|
Number of Patients With Hemodialysis
Time Frame: 60 days
|
60 days
|
|
Number of Patients With Continuous Renal Replacement Therapies (CRRT)
Time Frame: 60 days
|
60 days
|
|
Number of Patients With Peritoneal Dialysis
Time Frame: 60 days
|
60 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David J. Cohen, MD, Columbia University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAT0142
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on Clazakizumab
-
Cedars-Sinai Medical CenterCompleted
-
Medical University of ViennaCharite University, Berlin, Germany; University of Alberta; CSL BehringCompleted
-
NYU Langone HealthCompleted
-
Anne B. NewmanCSL BehringRecruitingImproving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study (RIGHT)Inflammation | FrailtyUnited States
-
The Methodist Hospital Research InstituteUnknown
-
Stanley Jordan, MDActive, not recruitingKidney Transplant Rejection | Kidney Transplant; Complications | Antibody-mediated Rejection | Transplant Glomerulopathy | Transplant Glomerulopathy - Late Form | Transplant Glomerulopathy - Early FormUnited States
-
CSL BehringCompletedRheumatoid ArthritisItaly, United States, France, Argentina, Mexico, Japan, Canada, Hungary, South Africa
-
CSL BehringActive, not recruitingEnd Stage Kidney Disease | Atherosclerotic Cardiovascular DiseaseUnited States, Australia, Belgium, Canada, Germany
-
Stanley Jordan, MDActive, not recruitingKidney Failure, Chronic | End-Stage Renal Disease | Kidney Transplant; Complications | Antibody-mediated Rejection | Kidney Transplant Failure and Rejection | Transplant;Failure,Kidney | Transplant GlomerulopathyUnited States
-
CSL BehringTerminatedCrohn's DiseaseGermany, India, Korea, Republic of, Taiwan, United States, Hong Kong, Canada, Mexico, Austria, Switzerland, Israel, Italy, France, Poland, Netherlands, Hungary, Czechia, United Kingdom